The vascular endothelial growth factor (VEGF) is a critical mediator of the sight-threatening neovascular complication that defines nAMD (7, 8), and its inhibition by frequent intravitreal anti-VEGF therapies reduces the risk of legal blindness in patients by 50% (9). This evidence concerns the gene VEGFA and blindness (disorder).